<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Terrosa II-18 - EN PI clean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:2 2 8 3 7 5 5 2 3 4;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:inherit;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	layout-grid-mode:char;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:36.85pt;
	text-indent:-36.85pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:45.35pt;
	text-indent:-45.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:53.85pt;
	text-indent:-53.85pt;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:62.35pt;
	text-indent:-62.35pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.8in;
	text-indent:-.8in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.9in;
	text-indent:-.9in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:1.0in;
	text-indent:-1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:1.1in;
	text-indent:-1.1in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.MsoFootnoteReference
	{font-family:"Times New Roman",serif;
	vertical-align:super;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
em
	{font-family:"Times New Roman",serif;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	background:navy;
	font-size:1.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	font-family:"Cambria",serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-weight:bold;
	font-style:italic;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";}
span.Heading2Char1
	{mso-style-name:"Heading 2 Char1";
	mso-style-link:"Heading 2";
	font-weight:bold;}
p.StyleHeading311ptLeft0cmFirstline0cmBefore0, li.StyleHeading311ptLeft0cmFirstline0cmBefore0, div.StyleHeading311ptLeft0cmFirstline0cmBefore0
	{mso-style-name:"Style Heading 3 + 11 pt Left\:  0 cm First line\:  0 cm Before\:  0\.\.\.";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:45.35pt;
	text-indent:-45.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.apple-style-span
	{mso-style-name:apple-style-span;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Times New Roman",serif;}
span.italics
	{mso-style-name:italics;
	font-family:"Times New Roman",serif;}
span.longtext
	{mso-style-name:long_text;
	font-family:"Times New Roman",serif;}
span.CharChar5
	{mso-style-name:"Char Char5";
	font-family:"Times New Roman",serif;}
span.hps
	{mso-style-name:hps;
	font-family:"Times New Roman",serif;}
span.atn
	{mso-style-name:atn;
	font-family:"Times New Roman",serif;}
p.Revision1, li.Revision1, div.Revision1
	{mso-style-name:Revision1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.CM43, li.CM43, div.CM43
	{mso-style-name:CM43;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleJustifiedRight-2535pt, li.StyleJustifiedRight-2535pt, div.StyleJustifiedRight-2535pt
	{mso-style-name:"Style Justified Right\:  -25\.35 pt";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.css-gen2
	{mso-style-name:css-gen2;
	font-family:"inherit",serif;
	border:none windowtext 1.0pt;
	padding:0in;
	vertical-align:baseline;}
p.Dossiertext, li.Dossiertext, div.Dossiertext
	{mso-style-name:Dossiertext;
	margin:0in;
	text-align:justify;
	line-height:130%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	layout-grid-mode:char;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:594.95pt 841.9pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><em><span lang=EN-AU>&nbsp;</span></em></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
font-variant:small-caps;color:black'><br clear=all style='page-break-before:
always'>
</span></b>

<p class=MsoNormal style='text-autospace:none'><b><span lang=HU
style='font-variant:small-caps;color:black'><img width=21 height=18 id="Kép 1"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image001.png"
alt="BT_1000x858px"></span></b><span lang=EN-GB>This medicinal product is
subject to additional monitoring. This will allow quick identification of new
safety information. Healthcare professionals are asked to report any suspected
adverse reactions. See section 4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Terrosa 20&nbsp;micrograms/80&nbsp;microliters
solution for injection</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=FR>2.       QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></h2>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each dose of 80&nbsp;microliters contains
20&nbsp;micrograms of teriparatide*.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One cartridge of 2.4&nbsp;mL of solution
contains 600&nbsp;micrograms of teriparatide (corresponding to
250&nbsp;micrograms per mL).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>*Teriparatide, rhPTH(1-34), produced in <i>E.
coli</i>, using recombinant DNA technology, is identical to the 34-N-terminal
amino acid sequence of endogenous human parathyroid hormone.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>3.       PHARMACEUTICAL FORM</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Solution for injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Colourless, clear solution for injection
with a pH of 3.8&nbsp;–&nbsp;4.5.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>4.       CLINICAL PARTICULARS</span></h2>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1     Therapeutic indications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Terrosa is indicated
in adults.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Treatment of
osteoporosis in postmenopausal women and in men at increased risk of fracture
(see section 5.1). In postmenopausal women, a significant reduction in the
incidence of vertebral and non&#8209;vertebral fractures but not hip fractures
has been demonstrated.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Treatment of osteoporosis associated with
sustained systemic glucocorticoid therapy in women and men at increased risk
for fracture (see section 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2     Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The recommended dose
of Terrosa is 20&nbsp;micrograms administered once daily.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Patients should
receive supplemental calcium and vitamin D supplements if dietary intake is
inadequate.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The maximum total
duration of treatment with teriparatide should be 24&nbsp;months (see section
4.4). The 24-month course of teriparatide should not be repeated over a
patient’s lifetime.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Following cessation
of teriparatide therapy, patients may be continued on other osteoporosis
therapies.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><u><span lang=EN-GB style='font-size:11.0pt'>Special
populations</span></u></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Renal impairment</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Teriparatide must not be used in patients
with severe renal impairment (see section 4.3). In patients with moderate renal
impairment, teriparatide should be used with caution. No special caution is
required for patients with mild renal impairment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Hepatic
impairment</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>No data are
available in patients with impaired hepatic function (see section 5.3).
Therefore, teriparatide should be used with caution.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Paediatric
population and young adults with open epiphyses</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The safety and
efficacy of teriparatide in children and adolescents less than 18 years have
not been established. Teriparatide should not be used in paediatric patients
(less than 18 years), or young adults with open epiphyses.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Elderly</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Dosage adjustment based on age is not
required (see section 5.2).</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Terrosa should be
administered once daily by subcutaneous injection in the thigh or abdomen.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>It should be administered exclusively with
the Terrosa Pen reusable, multidose medicine delivery system and the injection
needles which are listed as compatible in the instructions which are provided
with the pen. The pen and injection needles are not included with Terrosa. However,
for the treatment initiation a cartridge and pen pack should be used containing
one carton of Terrosa cartridge and one carton of Terrosa Pen. Terrosa must not
be used with any other pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients must be trained to use the proper
injection techniques (see section 6.6). An instruction for use which is
included in the carton of the delivery system is also available to instruct
patients on the correct use of the pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The date of first injection should also be
written on the outer carton of Terrosa (see the provided space on the box:
{First use:}).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substance or to
any of the excipients listed in section 6.1.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pregnancy and
breast-feeding (see sections 4.4 and 4.6).</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pre-existing
hypercalcaemia.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Severe renal impairment.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Metabolic bone diseases
(including hyperparathyroidism and Paget’s disease of the bone) other than
primary osteoporosis or glucocorticoid-induced osteoporosis.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Unexplained elevations
of alkaline phosphatase.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Prior external beam or
implant radiation therapy to the skeleton.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Patients with skeletal
malignancies or bone metastases should be excluded from treatment with
teriparatide.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Serum and urine
calcium</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In normocalcaemic
patients, slight and transient elevations of serum calcium concentrations have
been observed following teriparatide injection. Serum calcium concentrations
reach a maximum between 4 and 6 hours and return to baseline by 16 to 24 hours
after each dose of teriparatide. Therefore, if blood samples for serum calcium
measurements are taken, this should be done at least 16 hours after the most
recent teriparatide injection. Routine calcium monitoring during therapy is not
required.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Teriparatide may
cause small increases in urinary calcium excretion, but the incidence of
hypercalciuria did not differ from that in the placebo-treated patients in
clinical trials.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Urolithiasis</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Teriparatide has not
been studied in patients with active urolithiasis. Teriparatide should be used
with caution in patients with active or recent urolithiasis because of the
potential to exacerbate this condition.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Orthostatic
hypotension</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In short-term
clinical studies with teriparatide, isolated episodes of transient orthostatic
hypotension were observed. Typically, an event began within 4 hours of dosing
and spontaneously resolved within a few minutes to a few hours. When transient
orthostatic hypotension occurred, it happened within the first several doses,
was relieved by placing subjects in a reclining position, and did not preclude
continued treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Renal impairment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Caution should be exercised in patients
with moderate renal impairment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Younger adult
population</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Experience in the
younger adult population, including premenopausal women, is limited (see
section 5.1). Treatment should only be initiated if the benefit clearly
outweighs risks in this population.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Women of
childbearing potential should use effective methods of contraception during use
of teriparatide. If pregnancy occurs, teriparatide should be discontinued.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Duration of
treatment</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Studies in rats indicate an increased
incidence of osteosarcoma with long-term administration of teriparatide (see
section 5.3). Until further clinical data become available, the recommended
treatment time of 24&nbsp;months should not be exceeded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Traceability</span></u></p>

<p class=MsoNormal><span lang=EN-GB>In order to improve the traceability of
biological medicinal products, the name and the batch number of the
administered product should be clearly recorded.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Excipient</span></u></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product contains less than
1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to say essentially
“sodium-free”.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.5     Interaction with other medicinal products and other forms of
interaction</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In a study of 15
healthy subjects administered digoxin daily to steady state, a single teriparatide
dose did not alter the cardiac effect of digoxin. However, sporadic case
reports have suggested that hypercalcaemia may predispose patients to digitalis
toxicity. Because teriparatide transiently increases serum calcium,
teriparatide should be used with caution in patients taking digitalis.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Teriparatide has
been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide.
No clinically significant interactions were noted.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Co-administration of raloxifene or hormone replacement
therapy with teriparatide did not alter the effects of teriparatide on serum or
urine calcium or on clinical adverse events.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.6     Fertility, pregnancy and lactation</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Women of
childbearing potential / Contraception in females</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Women of childbearing potential should use
effective methods of contraception during use of teriparatide. If pregnancy
occurs, Terrosa should be discontinued.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa is contraindicated for use during
pregnancy (see section 4.3).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Breast-feeding</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa is contraindicated for use during
breast-feeding. It is not known whether teriparatide is excreted in human milk.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Fertility</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Studies in rabbits have shown reproductive
toxicity (see section 5.3). The effect of teriparatide on human foetal
development has not been studied. The potential risk for humans is unknown.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Teriparatide has no or negligible influence
on the ability to drive and use machines. Transient, orthostatic hypotension or
dizziness was observed in some patients. These patients should refrain from
driving or the use of machines until symptoms have subsided.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Summary of the
safety profile</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The most commonly
reported adverse reactions in patients treated with teriparatide are nausea,
pain in limb, headache and dizziness.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Tabulated list of
adverse reactions</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Of patients in the
teriparatide trials, 82.8% of the teriparatide patients and 84.5% of the
placebo patients reported at least 1 adverse event.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The adverse reactions associated with the
use of teriparatide in osteoporosis clinical trials and post-marketing exposure
are summarised in the table below.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following convention has been used for
the classification of the adverse reactions: very common (&#8805;1/10), common
(&#8805;1/100 to &lt;1/10), uncommon (&#8805;1/1,000 to &lt;1/100), and rare
(&#8805;1/10,000 to &lt;1/1,000).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Organ System Class</span></b></p>
   </td>
   <td width=114 valign=top style='width:85.7pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Very common</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Common</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Uncommon</span></b></p>
   </td>
   <td width=129 valign=top style='width:97.05pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
   style='color:black'>Rare</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Blood and
  lymphatic system disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Anaemia</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Immune system disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Anaphylaxis </span></p>
  </td>
 </tr>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Metabolism and nutrition
  disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hypercholesterol-aemia</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hypercalcaemia
  greater than 2.76&nbsp;mmol/L, hyperuricaemia </span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hypercalcaemia
  greater than 3.25&nbsp;mmol/L</span></p>
  </td>
 </tr>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Psychiatric disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Depression </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Nervous system disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Dizziness, headache, </span><span lang=EN-GB>sciatica,
  syncope</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Ear and
  labyrinth disorders </span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Vertigo </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:26.55pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Cardiac disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Palpitations</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Tachycardia</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:28.7pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:28.7pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Vascular disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.7pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.7pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hypotension</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.7pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.7pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:36.4pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>Respiratory,
  thoracic and mediastinal disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Dyspnoea</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Emphysema</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:36.4pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Gastrointestinal disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Nausea, vomiting,
  hiatus hernia, gastro-oesophageal reflux disease </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Haemorrhoids</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:36.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:43.1pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:43.1pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Skin and subcutaneous tissue disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.1pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Sweating increased
  </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:43.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:48.75pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>Musculoskeletal and connective tissue disorders</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Pain in limb </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Muscle cramps </span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>Myalgia, a</span><span lang=EN-GB>rthralgia, back cramp/pain*</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:48.75pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:34.4pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:34.4pt'>
  <p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Renal and
  urinary disorders </span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Urinary
  incontinence, polyuria, micturition urgency, nephrolithiasis</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:34.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Renal
  failure/impairment</span></p>
  </td>
 </tr>
 <tr style='height:49.1pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:black'>General disorders and administration site condition</span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Fatigue, chest
  pain, asthenia, mild and transient injection site events, including pain,
  swelling, erythema, localised bruising, pruritus and minor bleeding at
  injection site</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Injection site
  erythema, injection site reaction</span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Possible allergic
  events soon after injection: acute dyspnoea, oro/facial oedema, generalised
  urticaria, chest pain, oedema (mainly peripheral)</span></p>
  </td>
 </tr>
 <tr style='height:49.1pt'>
  <td width=129 valign=top style='width:96.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-AU>Investigations
  </span></b></p>
  </td>
  <td width=114 valign=top style='width:85.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Weight increased,
  cardiac murmur, alkaline phosphatase increased </span></p>
  </td>
  <td width=129 valign=top style='width:97.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:49.1pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>*Serious cases of back cramp or pain have
been reported within minutes of the injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Description of
selected adverse reactions</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In clinical trials
the following reactions were reported at a &#8805;1% difference in frequency
from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Teriparatide
increases serum uric acid concentrations. In clinical trials, 2.8% of
teriparatide patients had serum uric acid concentrations above the upper limit
of normal compared with 0.7% of placebo patients. However, the hyperuricaemia
did not result in an increase in gout, arthralgia, or urolithiasis.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In a large clinical trial, antibodies that
cross-reacted with teriparatide were detected in 2.8% of women receiving
teriparatide. Generally, antibodies were first detected following 12&nbsp;months
of treatment and diminished after withdrawal of therapy. There was no evidence
of hypersensitivity reactions, allergic reactions, effects on serum calcium, or
effects on Bone Mineral Density (BMD) response.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB>Reporting of
suspected adverse reactions</span></u></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions via <span style='background:lightgrey'>the national reporting
system listed in </span></span><span lang=EN-AU><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Signs and
symptoms</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Teriparatide has
been administered in single doses of up to 100&nbsp;micrograms and in repeated
doses of up to 60&nbsp;micrograms/day for 6&nbsp;weeks.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The effects of
overdose that might be expected include delayed hypercalcaemia and risk of
orthostatic hypotension. Nausea, vomiting, dizziness, and headache can also
occur.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Overdose
experience based on post-marketing spontaneous reports</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In post-marketing
spontaneous reports, there have been cases of medication error where the entire
contents (up to 800&nbsp;micrograms) of a teriparatide pen have been
administered as a single dose. Transient events reported have included nausea,
weakness/lethargy and hypotension. In some cases, no adverse events occurred as
a result of the overdose. No fatalities associated with overdose have been
reported.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Overdose
management</span></u></p>

<p class=MsoNormal><span lang=EN-GB>There is no specific antidote for
teriparatide. Treatment of suspected overdose should include transitory
discontinuation of teriparatide, monitoring of serum calcium, and
implementation of appropriate supportive measures, such as hydration.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>5.       PHARMACOLOGICAL PROPERTIES</span></h2>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.1     Pharmacodynamic properties</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Pharmacotherapeutic group: Calcium
homeostasis, parathyroid hormones and analogues, ATC code: H05AA02</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Terrosa is a
biosimilar medicinal product. Detailed information is available on the website
of the European Medicines Agency http://www.ema.europa.eu.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Mechanism of
action</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Endogenous
84-amino-acid parathyroid hormone (PTH) is the primary regulator of calcium and
phosphate metabolism in bone and kidney. Teriparatide (rhPTH(1-34)) is the
active fragment (1-34) of endogenous human parathyroid hormone. Physiological
actions of PTH include stimulation of bone formation by direct effects on bone
forming cells (osteoblasts) indirectly increasing the intestinal absorption of
calcium and increasing the tubular re-absorption of calcium and excretion of
phosphate by the kidney.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Pharmacodynamic
effects</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Teriparatide is a bone formation agent to
treat osteoporosis. The skeletal effects of teriparatide depend upon the
pattern of systemic exposure. Once-daily administration of teriparatide
increases apposition of new bone on trabecular and cortical bone surfaces by
preferential stimulation of osteoblastic activity over osteoclastic activity.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Clinical efficacy</span></u></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Risk factors</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Independent risk
factors, for example, low BMD, age, the existence of previous fracture, family
history of hip fractures, high bone turnover and low body mass index should be
considered in order to identify women and men at increased risk of osteoporotic
fractures who could benefit from treatment.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Premenopausal women
with glucocorticoid-induced osteoporosis should be considered at high risk for
fracture if they have a prevalent fracture or a combination of risk factors
that place them at high risk for fracture (e.g., low bone density [e.g.,
T-score &#8804;&#8722;2], sustained high dose glucocorticoid therapy [e.g.,
&#8805;7.5&nbsp;mg/day for at least 6&nbsp;months], high underlying disease
activity, low sex steroid levels).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Postmenopausal
osteoporosis</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The pivotal study included 1,637
postmenopausal women (mean age 69.5 years). At baseline, ninety percent of the
patients had one or more vertebral fractures, and on average, vertebral BMD was
0.82&nbsp;g/cm<sup>2</sup> (equivalent to a T-score = -&nbsp;2.6). All patients
were offered 1000&nbsp;mg calcium per day and at least 400&nbsp;IU vitamin D
per day. Results from up to 24&nbsp;months (median: 19&nbsp;months) treatment
with teriparatide demonstrate statistically significant fracture reduction
(Table 1). To prevent one or more new vertebral fractures, 11 women had to be
treated for a median of 19&nbsp;months.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Table 1</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=614 colspan=4 valign=top style='width:460.15pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>Fracture incidence in postmenopausal women</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=153 valign=top style='width:115.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>Placebo</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(N
  = 544) (%)</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>Teriparatide</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(N
  = 541) (%)</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>Relative risk (95% CI) vs. placebo</span></p>
  </td>
 </tr>
 <tr>
  <td width=153 valign=top style='width:115.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>New vertebral</span></p>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>fracture
  (&#8805;1) <sup>a</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>14.3</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>5.0 <sup>b</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>0.35</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.22,
  0.55)</span></p>
  </td>
 </tr>
 <tr>
  <td width=153 valign=top style='width:115.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Multiple vertebral
  fractures (&#8805;2) <sup>a</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>4.9</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>1.1 <sup>b</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>0.23</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>(0.09,
  0.60)</span></p>
  </td>
 </tr>
 <tr>
  <td width=153 valign=top style='width:115.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=FR style='font-size:11.0pt'>Non-vertebral
  fragility fractures <sup>c</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>5.5%</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>2.6% <sup>d</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>0.47</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(0.25, 0.87)</span></p>
  </td>
 </tr>
 <tr>
  <td width=153 valign=top style='width:115.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default><span lang=EN-GB style='font-size:11.0pt'>Major
  non-vertebral fragility fractures<sup>c</sup> (hip, radius, humerus, ribs and
  pelvis)</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>3.9%</span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>1.5% <sup>d</sup></span></p>
  </td>
  <td width=153 valign=top style='width:115.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>0.38</span></p>
  <p class=Default align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(0.17, 0.86)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Abbreviations:
N = number of patients randomly assigned to each treatment group; CI =
confidence interval.</span></p>

<p class=Default><sup><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>a
</span></sup><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
incidence of vertebral fractures was assessed in 448 placebo and 444
teriparatide patients who had baseline and follow-up spine radiographs.</span></p>

<p class=Default><sup><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>b
</span></sup><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>p&#8804;0.001
compared with placebo.</span></p>

<p class=Default><sup><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>c
</span></sup><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>A
significant reduction in the incidence of hip fractures has not been
demonstrated.</span></p>

<p class=MsoNormal><sup><span lang=EN-GB>d </span></sup><span lang=EN-GB>p&#8804;0.025
compared with placebo.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>After 19&nbsp;months
(median) treatment, bone mineral density (BMD) had increased in the lumbar
spine and total hip, respectively, by 9% and 4% compared with placebo
(p&lt;0.001).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Post-treatment management: Following
treatment with teriparatide, 1,262 postmenopausal women from the pivotal trial
enrolled in a post-treatment follow-up study. The primary objective of the
study was to collect safety data of teriparatide. During this observational
period, other osteoporosis treatments were allowed and additional assessment of
vertebral fractures was performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>During a median of
18&nbsp;months following discontinuation of teriparatide, there was a 41%
reduction (p=0.004) compared with placebo in the number of patients with a
minimum of one new vertebral fracture.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>In an open-label
study, 503 postmenopausal women with severe osteoporosis and a fragility
fracture within the previous 3&nbsp;years (83% had received previous osteoporosis
therapy) were treated with teriparatide for up to 24&nbsp;months. At
24&nbsp;months, the mean increase from baseline in lumbar spine, total hip and
femoral neck BMD was 10.5%, 2.6 % and 3.9% respectively. The mean increase in
BMD from 18 to 24&nbsp;months was 1.4%, 1.2%, and 1.6% at the lumbar spine,
total hip and femoral neck, respectively.</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>A 24-month, randomised, double-blind,
comparator-controlled Phase 4 study included 1,360 postmenopausal women with
established osteoporosis. 680 subjects were randomised to teriparatide and 680
subjects were randomised to oral risedronate 35&nbsp;mg/week. At baseline, the
women had a mean age of 72.1&nbsp;years and a median of 2 prevalent vertebral
fractures; 57.9% of patients had received previous bisphosphonate therapy and
18.8% took concomitant glucocorticoids during the study. 1,013 (74.5%) patients
completed the 24-month follow-up. The mean (median) cumulative dose of
glucocorticoid was 474.3 (66.2) mg in the teriparatide arm and 898.0 (100.0) mg
in the risedronate arm. The mean (median) vitamin D intake for the teriparatide
arm was 1433&nbsp;IU/day (1400 IU/day) and for the risedronate arm was 1191&nbsp;IU/day
(900&nbsp;IU/day). For those subjects who had baseline and follow-up spine
radiographs, the incidence of new vertebral fractures was 28/516 (5.4%) in
teriparatide- and 64/533 (12.0%) in risedronate-treated patients, relative risk
(95% CI) = 0.44 (0.29-0.68), p&lt;0.0001. The cumulative incidence of pooled clinical
fractures (clinical vertebral and non vertebral fractures) was 4.8% in
teriparatide and 9.8% in risedronate-treated patients, hazard ratio (95% CI) =
0.48 (0.32-0.74), p=0.0009.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Male osteoporosis</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>437 patients (mean
age 58.7&nbsp;years) were enrolled in a clinical trial for men with hypogonadal
(defined as low morning free testosterone or an elevated FSH or LH) or
idiopathic osteoporosis. Baseline spinal and femoral neck bone mineral density
mean T-scores were -2.2 and -2.1, respectively. At baseline, 35% of patients
had a vertebral fracture and 59% had a non-vertebral fracture.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>All patients were offered 1000&nbsp;mg
calcium per day and at least 400&nbsp;IU vitamin D per day. Lumbar spine BMD
significantly increased by 3&nbsp;months. After 12&nbsp;months, BMD had
increased in the lumbar spine and total hip by 5% and 1%, respectively,
compared with placebo<b>. </b>However, no significant effect on fracture rates
was demonstrated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Glucocorticoid-induced
osteoporosis</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The efficacy of
teriparatide in men and women (N=428) receiving sustained systemic
glucocorticoid therapy (equivalent to 5&nbsp;mg or greater of prednisone for at
least 3&nbsp;months) was demonstrated in the 18-month primary phase of a
36-month, randomised, double-blind, comparator-controlled study (alendronate
10&nbsp;mg/day). Twenty-eight percent of patients had one or more radiographic
vertebral fractures at baseline. All patients were offered 1000&nbsp;mg calcium
per day and 800&nbsp;IU vitamin D per day.</span></p>

<p class=MsoNormal><span lang=EN-GB>This study included postmenopausal women
(N=277), premenopausal women (N=67), and men (N=83). At baseline, the
postmenopausal women had a mean age of 61 years, mean lumbar spine BMD T score
of &#8722;2.7, median prednisone equivalent dose of 7.5&nbsp;mg/day, and 34%
had one or more radiographic vertebral fractures; premenopausal women had a
mean age of 37 years, mean lumbar spine BMD T score of &#8722;2.5, median
prednisone equivalent dose of 10&nbsp;mg/day, and 9% had one or more
radiographic vertebral fractures; and men had a mean age of 57&nbsp;years, mean
lumbar spine BMD T score of &#8722;2.2, median prednisone equivalent dose of
10&nbsp;mg/day, and 24% had one or more radiographic vertebral fractures.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Sixty-nine percent
of patients completed the 18-month primary phase. At the 18&nbsp;month
endpoint, teriparatide significantly increased lumbar spine BMD (7.2%) compared
with alendronate (3.4%) (p&lt;0.001). Teriparatide increased BMD at the total
hip (3.6%) compared with alendronate (2.2%) (p&lt;0.01), as well as at the
femoral neck (3.7%) compared with alendronate (2.1%) (p&lt;0.05). In patients
treated with teriparatide, lumbar spine, total hip and femoral neck BMD
increased between 18 and 24&nbsp;months by an additional 1.7%, 0.9%, and 0.4%,
respectively.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>At 36&nbsp;months,
analysis of spinal X-rays from 169 alendronate patients and 173 teriparatide
patients showed that 13 patients in the alendronate group (7.7%) had
experienced a new vertebral fracture compared with 3 patients in the
teriparatide group (1.7%) (p=0.01). In addition, 15 of 214 patients in the
alendronate group (7.0%) had experienced a non-vertebral fracture compared with
16 of 214 patients in the teriparatide group (7.5%) (p=0.84).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In premenopausal women, the increase in BMD
from baseline to 18&nbsp;month endpoint was significantly greater in the
teriparatide group compared with the alendronate group at the lumbar spine
(4.2% versus &#8722;1.9%; p&lt;0.001) and total hip (3.8% versus 0.9%;
p=0.005). However, no significant effect on fracture rates was demonstrated.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><u><span lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal><span lang=EN-GB>The volume of distribution is approximately
1.7&nbsp;L/kg. The half-life of teriparatide is approximately 1&nbsp;hour when
administered subcutaneously, which reflects the time required for absorption
from the injection site.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal><span lang=EN-GB>No metabolism or excretion studies have
been performed with teriparatide but the peripheral metabolism of parathyroid
hormone is believed to occur predominantly in liver and kidney.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Teriparatide is eliminated through hepatic
and extra-hepatic clearance (approximately 62&nbsp;L/hr in women and
94&nbsp;L/hr in men).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><u><span lang=EN-GB style='font-size:11.0pt'>Elderly</span></u></p>

<p class=MsoNormal><span lang=EN-GB>No differences in teriparatide
pharmacokinetics were detected with regard to age (range 31 to 85&nbsp;years).
Dosage adjustment based on age is not required.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.3     Preclinical safety data</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Teriparatide was not
genotoxic in a standard battery of tests. It produced no teratogenic effects in
rats, mice or rabbits. There were no important effects observed in pregnant
rats or mice administered teriparatide at daily doses of 30 to
1000&nbsp;micrograms/kg. However, foetal resorption and reduced litter size
occurred in pregnant rabbits administered daily doses of 3 to
100&nbsp;micrograms/kg. The embryotoxicity observed in rabbits may be related
to their much greater sensitivity to the effects of PTH on blood ionised
calcium compared with rodents.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Rats treated with
near-life time daily injections had dose-dependent exaggerated bone formation
and increased incidence of osteosarcoma most probably due to an epigenetic
mechanism. Teriparatide did not increase the incidence of any other type of
neoplasia in rats. Due to the differences in bone physiology in rats and
humans, the clinical relevance of these findings is probably minor. No bone
tumours were observed in ovariectomised monkeys treated for 18&nbsp;months or
during a 3-year follow-up period after treatment cessation. In addition, no
osteosarcomas have been observed in clinical trials or during the post treatment
follow-up study.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Animal studies have shown that severely
reduced hepatic blood flow decreases exposure of PTH to the principal cleavage
system (Kupffer cells) and consequently clearance of PTH(1-84).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></h2>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Glacial acetic
acid</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Mannitol</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Metacresol</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Sodium acetate
trihydrate</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Hydrochloric
acid (for pH adjustment)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Sodium
hydroxide (for pH adjustment)</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Water for
injections</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the absence of compatibility studies,
this medicinal product must not be mixed with other medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Chemical in-use stability has been
demonstrated for 28&nbsp;days at 2&nbsp;–&nbsp;8&nbsp;°C.</span></p>

<p class=MsoNormal><span lang=EN-GB>From a microbiological point of view, once
opened, the product may be stored for a maximum of 28&nbsp;days within its
shelf life at 2&nbsp;°C to 8&nbsp;°C.</span></p>

<p class=MsoNormal><span lang=EN-GB>Other in-use storage times and conditions
are the responsibility of the user.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4     Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator (2&nbsp;°C –
8&nbsp;°C). After insertion of the cartridge into the pen, the combined pen and
cartridge should be returned to the refrigerator immediately after use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze. Keep the cartridge in the
outer carton in order to protect from light.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not store the injection device with the
needle attached. Do not remove the cartridge from the pen after first use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For storage conditions after first opening
of the medicinal product, see section 6.3.</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.5     Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>3&nbsp;mL</span><span lang=EN-GB> cartridge
(siliconised Type I glass), with a plunger stopper and disc seal (aluminium and
rubber liner seals), packed in a plastic tray sealed with lid foil and packed in
a carton.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each cartridge contains 2.4&nbsp;mL of
solution corresponding to 28 doses of 20&nbsp;micrograms (per
80&nbsp;microliters).</span></p>

<p class=MsoNormal><span lang=EN-GB>Pack sizes: </span></p>

<p class=MsoNormal><span lang=FR>Terrosa 20&nbsp;micrograms/80&nbsp;microliters
solution for injection:</span></p>

<p class=MsoNormal><span lang=EN-GB>1 or 3 cartridges.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa cartridge and pen pack:</span></p>

<p class=MsoNormal><span lang=EN-GB>1 carton of Terrosa cartridge </span><span
lang=EN-AU>(</span><span lang=EN-GB>containing 1 cartridge) and 1 carton of
Terrosa Pen (containing 1 pen).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><a name=10></a><b><span
lang=EN-GB>6.6     Special precautions for disposal and other handling</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa is supplied in a cartridge. Terrosa
cartridges are to be used in Terrosa Pen reusable, multidose pen device
exclusively and must not be used with any other pen. No needles are supplied
with this medicinal product.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each cartridge and pen should be used by
only one patient. The pen can be used with compatible pen needles. These are
listed in the instruction for use for the pen. A new, sterile pen needle must
be used for every injection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The expiry date on the cartridge label must
always be checked before inserting the cartridge into Terrosa Pen. To avoid
medication errors make sure that the date when starting to use a new cartridge
is at least 28&nbsp;days before its expiry date.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Before using the pen device for the first
time, the patient should read and understand the instructions on how to use the
pen which are provided with the pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>After each injection, the pen should be
returned to the refrigerator. After the first use, the cartridge should not be
removed from the pen during the 28&nbsp;days of usage.</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa must not be transferred to a
syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB>Empty cartridges must not be refilled.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa should not be used if the solution
is cloudy, coloured or contains visible particles.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Any unused product or waste material should
be disposed of in accordance with local requirements.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>7.       MARKETING AUTHORISATION HOLDER</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Gedeon Richter Plc.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Gyömr&#337;i út
19-21.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>1103 Budapest</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>8.       MARKETING AUTHORISATION
NUMBER(S)</span></h2>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal>EU/<span style='color:black'>1/16/1159/001</span> <span
style='background:lightgrey'>[</span><span style='background:lightgrey'>1 cartridge]</span></p>

<p class=MsoNormal>EU/<span style='color:black'>1/16/1159/002</span> <span
style='background:lightgrey'>[3 </span><span style='background:lightgrey'>cartridges]</span></p>

<p class=MsoNormal>EU/1/16/1159/003 <span style='background:lightgrey'>[cartridge
and pen pack]</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>9.       DATE OF FIRST AUTHORISATION /
RENEWAL OF THE AUTHORISATION</span></h2>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<h1 style='margin:0in;text-indent:0in'><span lang=EN-GB style='font-weight:
normal'>Date of first authorisation: 04 January 2017</span></h1>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>10.     DATE OF REVISION OF THE TEXT</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Detailed information on this product is
available on the website of the European Medicines Agency </span><span
lang=EN-AU><a href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a></span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-top:0in;margin-right:70.8pt;
margin-bottom:0in;margin-left:85.05pt;margin-bottom:.0001pt;text-align:center;
text-indent:-35.4pt'><b><span lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>A.        MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>B.        CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>C.        OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>D.        CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.      MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><u><span
lang=EN-AU style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><u><span
lang=EN-AU style='color:black'>Name and address of the manufacturer of the
biological active substance</span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><u><span
lang=EN-AU style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=DE-AT style='color:black'>Richter-Helm BioLogics GmbH &amp; Co. </span><span
lang=DE style='color:black'>KG<br>
Dengelsberg<br>
24796 Bovenau<br>
GERMANY</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><u><span
lang=DE style='color:black'><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><u><span
lang=EN-AU style='color:black'>Name and address of the manufacturer responsible
for batch release</span></u></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=DE style='color:black'>Gedeon Richter Plc.<br>
Gyömr&#337;i út 19-21 <br>
1103 Budapest<br>
HUNGARY</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=DE style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=DE style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>Medicinal product subject to medical
prescription.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF
THE MARKETING AUTHORISATION </span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;text-autospace:none'><span
lang=EN-AU style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-AU style='color:black'>Periodic safety update
reports (PSURs)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>The requirements for submission of PSURs for
this medicinal product are set out in the list of Union reference dates (EURD
list) provided for under Article 107c(7) of Directive 2001/83/EC and any
subsequent updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD
TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:0in;text-indent:0in;text-autospace:none'><span
lang=EN-AU style='font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-AU style='color:black'>Risk management plan
(RMP)</span></b></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>The marketing authorisation holder (MAH) shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any
agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:6.0pt;text-autospace:none'><span
lang=EN-AU style='color:black'>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-10.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-10.35pt'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached. </span></p>

<b><span lang=EN-AU style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-AU>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span></b>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></h2>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING  </span></h2>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON FOR CARTRIDGE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa
20&nbsp;micrograms/80&nbsp;microliters solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>teriparatide </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each dose of 80&nbsp;microliters contains
20&nbsp;micrograms of teriparatide.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each cartridge contains 28 doses of
20&nbsp;micrograms (per 80&nbsp;microliters).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Glacial acetic acid,<span style='color:
black'> sodium acetate trihydrate, mannitol, metacresol, </span>water for
injections, hydrochloric acid </span><span lang=HU>(for pH adjustment) </span><span
lang=EN-GB>and sodium hydroxide</span><span lang=HU> (for pH adjustment)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Solution for
injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 cartridge</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>3 cartridges</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>28 doses</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>3x28 doses</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>Use only with Terrosa Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%;background:lightgrey'>QR code to be included</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-AU><a
href="http://www.terrosapatient.com"><span lang=HU style='line-height:115%'>www.terrosapatient.com</span></a></span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OF THE
SIGHT AND REACH OF CHILDREN </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not remove the cartridge from the pen
during the 28 days of use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP  </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=HU>Discard the cartridge 28 days after the first
use.</span></p>

<p class=MsoNormal><span lang=HU>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-GB style='line-height:
115%'>First use: <span style='background:lightgrey'>1.</span>
......................./<span style='background:lightgrey'>2.
........................</span>/<span style='background:lightgrey'>3.
........................<i>{the grey-shaded text refers to the 3x pack size}</i></span></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the cartridge in the outer carton in
order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OR WASTE
MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>APPROPRIATE
</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>Gedeon Richter Plc.</span></p>

<p class=MsoNormal><span lang=DE>Gyömr&#337;i út 19-21.</span></p>

<p class=MsoNormal><span lang=EN-GB>1103 Budapest</span></p>

<p class=MsoNormal><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>EU/</span><span lang=EN-AU style='color:black'>1/16/1159/001</span><span
lang=EN-AU> </span><span lang=FR style='background:lightgrey'>[</span><span
lang=FR style='background:lightgrey'>1 cartridge]</span><span lang=FR> </span></p>

<p class=MsoNormal><span lang=FR style='background:lightgrey'>EU/</span><span
lang=EN-AU style='color:black;background:lightgrey'>1/16/1159/002</span><span
lang=FR style='background:lightgrey'> [3 </span><span lang=FR style='background:
lightgrey'>cartridges]</span><span lang=FR> </span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>13.     BATCH
NUMBER </span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB> </span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>16.     INFORMATION
IN BRAILLE </span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Terrosa cartridge</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>17.     UNIQUE
IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=FR style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>2D barcode
carrying the unique identifier included</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER – HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING  </span></h2>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OUTER
CARTON FOR CARTRIDGE AND PEN PACK</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa
20&nbsp;micrograms/80&nbsp;microliters solution for injection </span></p>

<p class=MsoNormal><span lang=EN-GB>teriparatide </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each dose of 80&nbsp;microliters contains
20&nbsp;micrograms of teriparatide.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each cartridge contains 28 doses of 20&nbsp;micrograms
(per 80&nbsp;microliters).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Glacial acetic acid,<span style='color:
black'> sodium acetate trihydrate, mannitol, metacresol, </span>water for
injections, hydrochloric acid </span><span lang=HU>(for pH adjustment) </span><span
lang=EN-GB>and sodium hydroxide</span><span lang=HU> (for pH adjustment)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Solution for
injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 Terrosa cartridge </span></p>

<p class=MsoNormal><span lang=EN-GB>1 Terrosa Pen</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>28 doses</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not to be sold separately.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-AU>The cartridge and pen pack should be used
for treatment initiation.</span><span lang=EN-GB> Do not remove the cartridge
from the pen during the 28 days of use.</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>Use only with Terrosa Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Read both the package leaflet of Terrosa
cartridge and the instructions for use of the Terrosa Pen before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%;background:lightgrey'>QR code to be included</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-AU><a
href="http://www.terrosapatient.com"><span lang=HU style='line-height:115%'>www.terrosapatient.com</span></a></span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OF THE
SIGHT AND REACH OF CHILDREN </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=HU>Discard the cartridge 28 days after the first
use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OR WASTE
MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>APPROPRIATE
</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>          </span></p>

<p class=MsoNormal style='text-indent:28.35pt'><span lang=DE-AT>Gedeon Richter
Plc.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'><span lang=DE-AT>Gyömr&#337;i út
19-21.</span></p>

<p class=MsoNormal style='text-indent:28.35pt'><span lang=EN-GB>1103 Budapest</span></p>

<p class=MsoNormal style='text-indent:28.35pt'><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/16/1159/003</span><span lang=FR>    <span
style='background:lightgrey'>[</span><span style='background:lightgrey'>cartridge
and pen pack]</span></span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>13.     BATCH
NUMBER </span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>16.     INFORMATION
IN BRAILLE </span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Terrosa cartridge and pen</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>17.     UNIQUE
IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=FR style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>2D barcode
carrying the unique identifier included</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER – HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC</span></p>

<p class=MsoNormal><span lang=EN-GB>SN</span></p>

<p class=MsoNormal><span lang=EN-GB>NN</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>PARTICULARS
TO APPEAR ON THE OUTER PACKAGING  </span></h2>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>INNER
CARTON FOR CARTRIDGE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>no blue box is included</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa
20&nbsp;micrograms/80&nbsp;microliters solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>teriparatide </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each dose of 80&nbsp;microliters contains
20&nbsp;micrograms of teriparatide.</span></p>

<p class=MsoNormal><span lang=EN-GB>Each cartridge contains 28 doses of 20&nbsp;micrograms
(per 80&nbsp;microliters).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Glacial acetic acid,<span style='color:
black'> sodium acetate trihydrate, mannitol, metacresol, </span>water for
injections, hydrochloric acid </span><span lang=HU>(for pH adjustment) </span><span
lang=EN-GB>and sodium hydroxide</span><span lang=HU> (for pH adjustment)</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:lightgrey'>Solution for
injection</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>1 cartridge</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>28 doses</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>Use only with Terrosa Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal><span lang=EN-GB>Subcutaneous use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%;background:lightgrey'>QR code to be included</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-AU><a
href="http://www.terrosapatient.com"><span lang=HU style='line-height:115%'>www.terrosapatient.com</span></a></span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OF THE
SIGHT AND REACH OF CHILDREN </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not remove the cartridge from the pen
during the 28 days of use.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP  </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=HU>Discard the cartridge 28 days after the first
use.</span></p>

<p class=MsoNormal><span lang=HU>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-GB style='line-height:
115%'>First use:  .......................</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not freeze.</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep the cartridge in the outer carton in
order to protect from light.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>OR WASTE
MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF </span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>APPROPRIATE
</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE>Gedeon Richter Plc.</span></p>

<p class=MsoNormal><span lang=DE>Gyömr&#337;i út 19-21.</span></p>

<p class=MsoNormal><span lang=EN-GB>1103 Budapest</span></p>

<p class=MsoNormal><span lang=EN-GB>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S) </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>13.     BATCH
NUMBER </span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>16.     INFORMATION
IN BRAILLE </span></b></p>

</div>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>Terrosa cartridge</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<p class=MsoNormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=FR>17.     UNIQUE
IDENTIFIER – 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=FR style='background:lightgrey'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.     UNIQUE
IDENTIFIER – HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:0in 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></h2>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON BLISTERS OR STRIPS </span></h2>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>LID FOIL</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>1.       NAME OF THE MEDICINAL PRODUCT </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa
20&nbsp;micrograms/80&nbsp;microliters solution for injection</span></p>

<p class=MsoNormal><span lang=EN-GB>teriparatide </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       NAME
OF THE MARKETING AUTHORISATION HOLDER </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>((RG-emblem))</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       OTHER
</span></b></p>

</div>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=EN-AU>Subcutaneous use <i><span
style='color:black;background:#BFBFBF'>{1x}</span></i></span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%;background:lightgrey'>SC</span><span lang=EN-AU style='color:black;
background:#BFBFBF'>                        </span><i><span lang=EN-AU
style='background:lightgrey'>{3x}</span></i></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>&nbsp;</span></p>

<p class=MsoNormal><span lang=HU>Store in a refrigerator.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=HU>28x</span></p>

<p class=MsoNormal><span lang=HU>&nbsp;</span></p>

<p class=MsoNormal style='line-height:115%'><span lang=HU style='line-height:
115%'>Use only with Terrosa Pen.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<h2 style='margin-bottom:0in;border:none;padding:0in'><span lang=EN-GB>MINIMUM
PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS </span></h2>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>LABEL </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa 20&nbsp;mcg/80&nbsp;mcL injection </span></p>

<p class=MsoNormal><span lang=EN-GB>teriparatide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>SC </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>2.       METHOD
OF ADMINISTRATION </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>3.       EXPIRY
DATE </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>4.       BATCH
NUMBER </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>5.       CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>2.4&nbsp;mL</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>6.       OTHER 
</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt;background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='background:lightgrey'>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<h2 align=center style='margin:0in;text-align:center;text-indent:0in'><span
lang=EN-GB>Package leaflet: Information for the user</span></h2>

<p class=Default align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default align=center style='text-align:center'><b><span lang=EN-GB
style='font-size:11.0pt'>Terrosa 20&nbsp;micrograms/80&nbsp;microliters
solution for injection</span></b></p>

<p class=Default align=center style='text-align:center'><span lang=EN-GB
style='font-size:11.0pt'>teriparatide</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=HU><img border=0 width=21 height=18 id="Kép 4"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image002.png"
alt="BT_1000x858px"></span><span lang=EN-GB>This medicine is subject to
additional monitoring. This will allow quick identification of new safety
information. You can help by reporting any side effects you may get. See the
end of section 4 for how to report side effects.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Read all of this
leaflet carefully before you start using this medicine because it contains
important information for you.</span></b></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-        Keep this leaflet. You may need to
read it again.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-        If you have any further questions,
ask your doctor or pharmacist.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-        This medicine has been prescribed
for you only. Do not pass it on to others. It may harm them, even if their
signs of illness are the same as yours.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-        If you get any side effects, talk
to your doctor or pharmacist. This includes any possible side effects not
listed in this leaflet. See section 4.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>What is in this
leaflet</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>1.       What Terrosa is and what it is
used for</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>2.       What you
need to know before you use Terrosa</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>3.       How to use
Terrosa</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>4.       Possible
side effects</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>5        How to
store Terrosa</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>6.       Contents of
the pack and other information</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>What Terrosa is and what it is used for</span></h2>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Terrosa contains the
active substance teriparatide that is used to make the bones stronger, and to
reduce the risk of fractures by stimulating bone formation.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa is used to treat osteoporosis in
adults. Osteoporosis is a disease that causes your bones to become thin and
fragile. This disease is especially common in women after the menopause, but it
can also occur in men. Osteoporosis is also common in patients receiving
medicines called corticosteroids.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>What you need to know before you use Terrosa</span></h2>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Do not use
Terrosa</span></b></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are allergic to
teriparatide or any of the other ingredients of this medicine (listed in
section 6).</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have high levels
of calcium in your blood (hypercalcaemia).</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you suffer from
serious kidney problems.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have ever had
bone cancer or if other cancers have spread (metastasised) to your bones.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have certain
bone diseases. If you have a bone disease, tell your doctor.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have unexplained
high levels of alkaline phosphatase in your blood, which means you might have
Paget’s disease of bone (disease with abnormal bone changes). If you are not
sure, ask your doctor.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have had
radiation therapy involving your bones.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you are pregnant or
breast-feeding.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Warnings and
precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa may increase calcium in your blood
or urine.</span></p>

<p class=MsoNormal><span lang=EN-GB>Talk to your doctor before or while using
Terrosa:</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you have continuing
nausea, vomiting, constipation, low energy, or muscle weakness. These may be
signs there is too much calcium in your blood.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you suffer from
kidney stones or have had kidney stones.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>if you suffer from
kidney problems (moderate renal impairment).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Some patients get
dizzy or get a fast heartbeat after the first few doses of Terrosa. For the
first doses, inject Terrosa in a place where you can sit or lie down right away
if you get dizzy.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The recommended
treatment time of 24 months should not be exceeded.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Before inserting a
cartridge in Terrosa Pen</span><span lang=EN-GB style='font-size:11.0pt'> w</span><span
lang=EN-GB style='font-size:11.0pt'>rite down the batch (Lot) number of the
cartridge and its first injection date on a calendar. The date of first
injection should also be recorded on the outer carton of Terrosa (see the
provided space on the box: {First use:}) (see section 3.).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa should not be used in growing
adults.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Children and
adolescents</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Terrosa should not
be used in children and adolescents (aged less than 18&nbsp;years).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Other medicines
and Terrosa</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Tell your doctor or
pharmacist if you are using, have recently used or might use any other
medicines.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>This is important,
because some medicines (e.g. digoxin/digitalis, a medicine used to treat heart
disease) may interact with teriparatide.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Pregnancy and
breast-feeding</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Do not use Terrosa
if you are pregnant or breast-feeding. If you are a woman of child-bearing
potential, you should use effective methods of contraception during use of
Terrosa. If you become pregnant while using Terrosa, Terrosa should be
discontinued. Ask your doctor or pharmacist for advice before taking any
medicine.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Driving and using
machines</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Some patients may
feel dizzy after injecting Terrosa. If you feel dizzy you should not drive or
use machines until you feel better.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Terrosa contains
sodium</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>This medicine
contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to
say essentially “sodium-free”.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to use Terrosa</span></h2>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Always use this
medicine exactly as your doctor has told you. Check with your doctor or
pharmacist if you are not sure.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p style='margin:0in;background:white'><span lang=EN-GB style='color:black'>The
recommended dose is 20&nbsp;micrograms (corresponding to 80&nbsp;microliters)
given once a day by injection under the skin (subcutaneous injection) in the
thigh or abdomen.</span></p>

<p class=MsoNormal><span lang=EN-GB>To help you remember to take your medicine,
inject it at about the same time each day. Terrosa can be injected at meal
times. Inject Terrosa each day for as long as your doctor prescribes it for
you. The total duration of treatment with Terrosa should not exceed 24&nbsp;months.
You should not receive more than one treatment course of 24&nbsp;months over
your lifetime.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Your doctor may
advise you to take Terrosa with calcium and vitamin D. Your doctor will tell
you how much you should take each day.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa can be given with or without food.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='color:black'>Terrosa cartridges are
designed to be used </span><span lang=EN-GB>only with the Terrosa Pen</span><span
lang=EN-GB> reusable, multidose </span><span lang=EN-GB style='color:black'>delivery
system and compatible pen needles.</span><span lang=EN-GB> The pen and
injection needles are not included with Terrosa. However, for treatment
initiation a cartridge and pen pack should be used containing one carton of
Terrosa cartridge and one carton of Terrosa Pen.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Before the first
use, insert the cartridge into the pen. For the correct use of this medicine it
is very important to closely follow the detailed Instructions for Use of your
pen which are provided with the pen.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Use a new injection
needle for each injection to prevent contamination and safely dispose of the
needle after use.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Never store your pen
with the needle attached.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Never share your pen
with others.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Do not use your </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>Terrosa Pen</span><span
lang=EN-GB style='font-size:11.0pt'> to inject any other medicine (e.g.
insulin).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The pen is
customised for use with Terrosa only.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Do not refill the
cartridge.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Do not transfer the
medicine into a syringe.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You should inject Terrosa shortly after you
take the pen with inserted cartridge out of the refrigerator. Put the pen with
inserted cartridge back into the refrigerator immediately after you have used
it. Do not remove the cartridge from the pen after each use. Store it in the
cartridge sleeve during the whole 28-day treatment period.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Preparing the pen for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;vertical-align:
baseline'><span lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='color:black'>To ensure the correct
administration of Terrosa always read the Instructions for Use of</span><span
lang=EN-GB style='color:#0070C0'> </span><span lang=EN-GB>Terrosa Pen</span><span
lang=EN-GB style='color:black'>, which is included in the carton of the pen.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Wash your hands before handling the cartridge or
pen.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Check the expiry date
on the cartridge label before inserting the cartridge into the pen. Make sure
that there are at least 28&nbsp;days remaining before its expiry date. Insert
the cartridge into the pen before the first use as detailed in the pen
instructions. Write down the batch (Lot) number of each cartridge and its first
injection date on a calendar. The date of first injection should also be
recorded on the outer carton of Terrosa (see the provided space on the box:
{First use:}).</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>After inserting a new
cartridge and before the first injection from this cartridge prime the pen
according to the instructions which are provided. Do not prime again after the
first dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Injecting Terrosa</span></b></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Before you inject
Terrosa, clean your skin where you intend to inject (thigh or abdomen) as
instructed by your doctor.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt;text-autospace:none'><span
lang=EN-GB>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Gently hold a fold of cleansed skin and insert
the needle straight into the skin. Press the push button and hold it pressed in
until the dose indication has returned to the start position.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>After your injection,
leave the needle in the skin for six seconds to make sure that you receive the
whole dose.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>As soon as you have
finished the injection, attach the outer needle protective cap on the pen
needle and screw the cap anti-clockwise to remove the pen needle. This will
keep the remaining Terrosa sterile and prevent leaking from the pen. It will
also stop air going back into the cartridge and the needle from clogging.</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Replace the cap on your
pen. Leave the cartridge in the pen.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>If you use more
Terrosa than you should</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If, by mistake, you
have used more Terrosa than you should, contact your doctor or pharmacist.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The expected effects
of overdose include nausea, vomiting, dizziness, and headache.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>If you forget to
use Terrosa</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If you forget an
injection or cannot use your medicine at your usual time</span><span
lang=EN-GB style='font-size:11.0pt'>, inject it as soon as possible on that
day. Do not use a double dose to make up for a forgotten dose. Do not take more
than one injection in the same day.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>If you stop using
Terrosa</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If you are
considering stopping Terrosa treatment, please discuss this with your doctor.
Your doctor will advise you and decide how long you should be treated with
Terrosa.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Possible side effects</span></h2>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Like all medicines,
this medicine can cause side effects, although not everybody gets them.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>The most common side
effects are pain in limb (which may affect more than 1 in 10 people). Other
common side effects (affecting up to 1 in 10 people) include feeling sick,
headache and dizziness. If you become dizzy (light-headed) after your
injection, you should sit or lie down until you feel better. If you do not feel
better, you should call a doctor before you continue treatment. Cases of
fainting have occured after teriparatide use.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If you have
discomfort around the area of the injection such as redness of the skin, pain,
swelling, itching, bruising or minor bleeding (which can occur in up to 1 in 10
people), this should clear up in a few days or weeks. Otherwise tell your
doctor.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Rarely, patients may suffer allergic
reactions consisting of breathlessness, swelling of the face, rash and chest
pain. These reactions usually occur soon after injection. In rare cases,
serious and potentially life-threatening allergic reactions including
anaphylaxis can occur.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Other side effects
include:</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Common</span></i><span
lang=EN-GB style='font-size:11.0pt'> (may affect up to 1 in 10 people):</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increase in blood
cholesterol levels</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>depression</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>nerve pain in the leg</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>feeling faint</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>spinning sensation</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>irregular heartbeats</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>breathlessness</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increased sweating</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>muscle cramps</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>loss of energy</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>tiredness</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>chest pain</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>low blood pressure</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>heartburn (painful or burning
sensation just below the breast bone)</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>vomiting</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>a hernia of the tube
that carries food to your stomach (hiatus hernia)</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>low haemoglobin or red
blood cell count (anaemia).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Uncommon</span></i><span
lang=EN-GB style='font-size:11.0pt'> (may affect up to 1 in 100 people):</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increased heart rate</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>abnormal heart sound</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>shortness of breath</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>piles (haemorrhoids)</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>leakage of urine</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increased need to pass
water</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>weight increase</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>kidney stones</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>pain in the muscles and
pain in the joints. Some patients have had severe back cramps or pain which led
to admission into hospital.</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increase in blood
calcium level</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increase in blood uric
acid level</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>increase in an enzyme
called alkaline phosphatase.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><i><span lang=EN-GB style='font-size:11.0pt'>Rare</span></i><span
lang=EN-GB style='font-size:11.0pt'> (may affect up to 1 in 1,000 people):</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>reduced kidney
function, including renal failure</span></p>

<p class=Default style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='font-size:11.0pt'>•<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>swelling, mainly in the
hands, feet and legs.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Reporting of side
effects</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>If you get any side
effects, talk to your doctor or pharmacist. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly
via <span style='background:lightgrey'>the national reporting system listed in </span></span><span
lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='font-size:11.0pt;background:lightgrey'>Appendix V</span></a></span><span
lang=EN-GB style='font-size:11.0pt'>. By reporting side effects you can help
provide more information on the safety of this medicine.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>How to store Terrosa</span></h2>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Keep this medicine
out of the sight and reach of children.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Do not use this
medicine after the expiry date which is stated on the carton and the cartridge
after EXP. The expiry date refers to the last day of that month.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Store in a
refrigerator (2&nbsp;°C – 8&nbsp;°C). Do not freeze.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Keep the cartridge
in the outer carton in order to protect from light.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>You can use Terrosa
for up to 28&nbsp;days after the first injection, as long as the cartridge/pen
with the cartridge inserted is stored in a refrigerator (2&nbsp;°C to
8&nbsp;°C).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Avoid placing the
cartridge close to the ice compartment of the refrigerator to prevent freezing.
Do not use Terrosa if it is, or has been, frozen.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Each cartridge
should be properly disposed of after 28&nbsp;days of first use, even if it is
not completely empty.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Terrosa contains a
clear and colourless solution. Do not use Terrosa if solid particles appear or
if the solution is cloudy or coloured.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not throw away any medicines via
wastewater or household waste. Ask your pharmacist how to throw away medicines
you no longer use. These measures will help protect the environment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h2 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:28.35pt;
text-indent:-28.35pt'><span lang=EN-GB>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Contents of the pack and other information</span></h2>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>What Terrosa
contains</span></b></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The active substance is
teriparatide. Each dose of 80&nbsp;microliters contains 20&nbsp;micrograms of
teriparatide. One cartridge of 2.4&nbsp;mL contains 600&nbsp;micrograms of
teriparatide (corresponding to 250&nbsp;micrograms per mL).</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>The other ingredients
are: glacial acetic acid, mannitol, metacresol, sodium acetate trihydrate,
hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment),
water for injections.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>What Terrosa
looks like and contents of the pack</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Terrosa is a colourless and clear solution.
It is supplied in a cartridge. Each cartridge contains 2.4&nbsp;mL of solution,
enough for 28 doses.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=FR style='font-size:11.0pt'>Terrosa
20&nbsp;micrograms/80&nbsp;microliters solution for injection:</span><span
lang=FR style='font-size:11.0pt'> </span><span lang=EN-GB style='font-size:
11.0pt'>1 or 3 cartridge(s) packed in a plastic tray sealed with lid foil and packed
in a carton.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Terrosa cartridge
and pen pack: 1 Terrosa cartridge packed in a plastic tray sealed with lid foil
and packed in a carton and 1 Terrosa Pen packed into a separate carton.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Not all pack sizes
may be marketed.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Marketing
Authorisation Holder and Manufacturer</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Gedeon Richter Plc.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Gyömr&#337;i út
19-21.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>1103 Budapest</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Hungary</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><b><span lang=EN-GB style='font-size:11.0pt'>Other sources of
information</span></b></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Detailed and updated
information on this product is available by scanning the QR code included below
or the outer carton with a smartphone.The same information is also available on
the following URL: </span><span lang=EN-GB><a
href="http://www.terrosapatient.com"><span style='font-size:11.0pt;color:black'>www.terrosapatient.com</span></a></span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;background:lightgrey'>QR
code to be included</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>Detailed information
on this medicine is available on the European Medicines Agency web site:</span></p>

<p class=MsoNormal><span lang=EN-AU><a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a></span></p>

<p class=MsoNormal><span class=MsoHyperlink><span lang=EN-AU><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<span class=MsoHyperlink><span lang=EN-AU style='font-size:11.0pt'><br
clear=all style='page-break-before:always'>
</span></span>

<p class=MsoNormal><span class=MsoHyperlink><span lang=EN-AU><span
 style='text-decoration:none'>&nbsp;</span></span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>Instructions for use </span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Terrosa Pen</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Re-usable pen injector to be used with Terrosa cartridges
for subcutaneous injections</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Always follow instructions provided below and on the back
page when using the Terrosa Pen.</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Terrosa Pen parts</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=242 height=426 id="Kép 5"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image003.png"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>push button;
display window; threaded rod; flange; Terrosa cartridge; peel foil; pen needle;
inner needle cap; outer needle cap; pen cap; cartridge holder, dosage knob,
housing</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Pen preparation - First use/changing cartridges</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Follow the
instructions every time you insert a new Terrosa cartridge into your Terrosa Pen.
Do not repeat this before each daily injection, otherwise you will not have
enough Terrosa for 28 days.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Read the
patient information leaflet for Terrosa cartridge provided separately.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A: Remove the
pen cap.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=217 height=173 id="Kép 6"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image004.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>B: Remove the
cartridge holder by turning it (bayonet coupling). </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=223 height=178 id="Kép 13"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image005.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>C: Remove the
empty cartridge, in the case of changing cartridge. Insert a new Terrosa
cartridge into the cartridge holder, with the metal crimped cap of the
cartridge first.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=223 height=167
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image006.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Write down the
first injection date of each new cartridge. This helps you to know when the 28
daily doses per cartridge are used. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>D: Push back
the threaded rod carefully with your finger, in a straight line and as far as
it will go. This is not necessary when the rod is already in the starting
position, such as at the very first use. The threaded rod cannot be pushed back
to the pen housing entirely.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=223 height=135 id="Kép 29"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image007.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>E: Attach the
cartridge holder to the housing by turning it 90 degrees, until it stops.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=208 height=198 id="Kép 30"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image008.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>F: Attach a new
pen needle as follows: </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Pull off the
peel foil.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB> </span><span
lang=HU><img border=0 width=221 height=109 id="Kép 31"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image009.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Screw the pen
needle clockwise onto the cartridge holder. Make sure that the pen needle is
attached correctly and sits firmly on the cartridge holder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=225 height=144 id="Kép 33"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image010.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Remove the
outer needle cap and save it.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=225 height=146 id="Kép 32"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image011.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Remove and
dispose the inner needle cap.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=232 height=149 id="Kép 34"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image012.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>While attaching
the needle some drops may escape, this is normal.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>G: Priming</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The pen must be
primed and tested after inserting a new cartridge and prior the first injection
from each cartridge.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Turn the dose
knob clockwise until you see a droplet sign on the dose display. Make sure that
the two indicator stripes are aligned. During dose dialling the pen provides an
audible clicking sound and a noticeable resistance.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=254 height=137 id="Kép 35"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image013.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Hold the pen with
the <b>needle pointing upwards</b>.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>• Press the
push button fully in. Hold it pressed in until the dose indication has turned
back to the start position. Some drops of medicine must be expelled from the
needle tip.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If no drops
emerge, repeat step G until you see some drops. Do not repeat step G more than
four times, but follow the instructions given under Troubleshooting section on
the back page. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=173 height=151 id="Kép 28"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image014.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Administration using the Terrosa Pen</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Wash your hands carefully with soap to minimise the risk of
infection.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Make sure you have ready:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• your Terrosa Pen with inserted cartridge</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• a compatible pen needle</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• a puncture-resistant sharps disposal container for used
needles.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>Do not use </span></b><span lang=EN-GB style='color:black'>the
pen if the <b>cartridge is cloudy, discoloured or contains particles.</b></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Read the patient information leaflet for Terrosa cartridge
provided separately.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>1. Attach the pen needle</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Use a new needle for every injection. Do not use the pen
needle if the packaging is damaged or not opened by yourself.</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>Note: </span></b><span lang=EN-GB style='color:black'>There
is no need to change the needle when using directly after the pen preparation.
In this case continue with step “2. Setting the dose and injection”.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Pull off the peel foil.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=221 height=109 id="Kép 37"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image009.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Screw the pen needle clockwise onto the cartridge holder.
Make sure that the pen needle is attached correctly and sits firmly on the
cartridge holder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=225 height=144 id="Kép 38"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image015.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Remove the outer needle cap and save it.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=225 height=146 id="Kép 39"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image016.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Remove and dispose the inner needle cap.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=232 height=149 id="Kép 40"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image012.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>While attaching the needle some drops may escape, this is
normal.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>2. Setting the dose and injection</span></b></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>Warning:</span></b><span lang=EN-GB style='color:black'>
Ensure the use of the correct drug liquid. Check the label of the cartridge
before its insertion into the cartridge holder.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• To set the fixed daily dose of 80&nbsp;microliters, turn
the dose knob clockwise until it stops and cannot be rotated any further. Make
sure the </span><span lang=EN-GB>display shows an arrow sign and<span
style='color:black'> it is aligned with the indicator stripe. During dose
dialling the pen provides an audible clicking sound and a noticeable
resistance. Do not try to force the dose knob any further.</span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU style='color:black'><img
border=0 width=243 height=131 id="Kép 41"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image017.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>Note: </span></b><span lang=EN-GB style='color:black'>If
the cartridge contains less than 80 microliters, the dose knob cannot be turned
clockwise up </span><span lang=EN-GB>to the arrow sign. In<span
style='color:black'> this case, remove the pen needle, change the cartridge and
proceed with priming according the pen preparation steps.</span></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Select an appropriate injection site and prepare your
skin as recommended by your doctor. Gently hold a skin fold between the thumb
and index finger. Insert the needle straight and gently into the skin, as shown
in the illustration.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU style='color:black'><img
border=0 width=210 height=142 id="Kép 20"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image018.png"></span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>Warning: </span></b><span lang=EN-GB style='color:black'>Prevent
the pen needle from bending or breaking. Do not tilt the pen after the needle
has been inserted into the skin. Tilting the pen may result in bending or
breaking of the needle. Broken needles can get stuck in the skin. Immediately
consult the doctor if a broken needle gets stuck in the skin.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Press the push button until the dose indication has
returned to the start position. Keep the needle in the skin fold for a further
6 seconds.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU><img border=0
width=195 height=186 id="Kép 27"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image019.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Pull out the pen slowly. Check if the display is at the
start position to make sure that the full dose has been injected.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU style='color:black'><img
border=0 width=268 height=139 id="Kép 7"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image020.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>3. Removing the pen needle</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Carefully attach the outer needle cap on the pen needle.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU style='color:black'><img
border=0 width=283 height=182 id="Kép 43"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image021.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Screw the needle cap anti-clockwise to remove the pen
needle. Dispose of it correctly, for example, in a puncture-resistant sharps
disposal container.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU style='color:black'><img
border=0 width=266 height=171 id="Kép 44"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image022.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>4. Re-attach pen cap</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Do not remove the cartridge from the Terrosa Pen before
it is empty.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Re-attach the pen cap after each use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=HU style='color:black'><img
border=0 width=284 height=227 id="Kép 45"
src="Terrosa%20II-18%20-%20EN%20PI%20clean_files/image023.jpg"></span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Put the Terrosa Pen, with the cartridge inserted, back
into the refrigerator between 2 and 8 °C immediately after use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:black'>Note for healthcare professionals</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Local, healthcare professional or institutional policies
may replace the instructions regarding needle handling and disposal.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Additional information</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The reusable fixed dose pen is designed for easy
administration of Terrosa to treat osteoporosis. Each Terrosa cartridge
contains 28 doses of fixed 80&nbsp;microlitres Terrosa. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Use your Terrosa Pen only as prescribed by your doctor, in
this instructions for use and the Terrosa package leaflet.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The Terrosa Pen can be used by self-injecting patients
above the age of 18&nbsp;years, healthcare professionals or third parties such
as, for instance, adult relatives.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The Terrosa Pen must not be used by blind or visually
impaired patients without help from a trained able-bodied person. Consult your
doctor in the case of hearing or handling problems.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>If you have any questions concerning the use of the Terrosa
Pen, contact our <b>customer service </b>at any time.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>telephone number: XXXXXXXXXXX</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>e-mail: XXXXXXXXXXX</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Compatible pen needles</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Ypsomed mylifeClickfine 29 to 31&nbsp;gauge (diameter
0.25 – 0.33&nbsp;mm) and 12, 10, 8 or 6&nbsp;mm length</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• BD Micro-Fine Ultraneedles 29 to 31&nbsp;gauge (diameter
0.25 – 0.33&nbsp;mm) and 12.7, 8 or 5&nbsp;mm length</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Pen needles from other manufacturers can be used according
to their stated compatibility details.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The <b>pen needles must be used only once </b>and the
Terrosa cartridge must be used by one person only.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Storage and care of Terrosa Pen</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Handle your pen with care. Do not drop your pen and avoid
knocking it against hard surfaces. Protect it from water, dust and moisture. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• A damp cloth is sufficient to clean the Terrosa Pen. Do
not use alcohol, other solvents or cleaning agents. Never immerse the Terrosa
Pen in water, as this could damage the pen.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Do not use your Terrosa Pen if it is damaged or if you
have any doubts about its correct functioning.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Transport and store the Terrosa Pen with inserted
cartridge at temperatures specified in the Terrosa package leaflet, provided
separately.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Store your Terrosa Pen, cartridges and pen needles out of
reach of children.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• Do not store the Terrosa Pen with a needle attached as
this may cause air bubbles to form in the cartridge.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Disposal of Terrosa Pen and used accessories</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The Terrosa Pen has a service life of two years. Before
disposing of the Terrosa Pen always remove the pen needle and the cartridge.
Needles and used cartridges must be disposed of separately and safely. The
Terrosa Pen can be disposed of according to the instructions of the local
authorities. </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><u><span lang=EN-GB
style='color:#003883'>Warnings</span></u></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Follow the instructions presented in this instructions for
use. If the instructions are not followed, there are risks of incorrect
medication, inaccurate dosage, disease transmission or infection. Seek
immediate medical advice if you have any health concern.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:#003883'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Warranty</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>The warranty covers manufacturing and material defects of
your Terrosa Pen for two years of use, from purchase. It is limited to
replacement of the pen. The warranty does not cover damages caused by:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• using cartridges other than Terrosa cartridges</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• improper or careless use, handling or cleaning</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• use contrary to the instructions for use </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• the pen being used with a medical device, accessories or
consumables other than those mentioned in this Instructions for use</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• dropping, impact, application of force, contact with
fluids</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>• other cases of exposure and wear, not in accordance with
the instructions for use.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
style='color:#003883'>Troubleshooting</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='color:black'>Follow the instructions given in the table if you have any
questions regarding the use of Terrosa Pen:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:#003883'>Question</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB
  style='color:#003883'>Answer</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>1. Small air
  bubbles are visible in the cartridge.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>A small air
  bubble will not affect the dose, or harm.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>2. Needle
  cannot be attached.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Use another
  needle instead. Contact customer service if the second needle cannot be
  attached.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>3. Needle is
  broken/curved/kinked.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Use another
  needle instead.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>4. During
  dose dialling the pen does not provide an audible signal.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not use
  this pen; contact customer service.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>5. No
  medicine comes out of the needle during pen preparation step “G: Priming”.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Change the
  needle and repeat the priming as described in pen preparation sections “F”
  and “G”.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If still no medicine
  is expelled, do not use this pen; contact customer service.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>6. The dose
  knob cannot be turned clockwise up to the arrow sign.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>The amount of
  Terrosa left in the cartridge is less than 80 microlitres. Change the
  cartridge and the pen needle and perform priming according to the pen
  preparation.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>7. Display
  does not return to start position after injection.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not repeat
  the injection on the same day.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Use a new
  needle for your injection on the following day.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Set the dose
  and complete the injection as described in section “2. Setting the dose and
  injection”.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>If the
  display still does not return to start position after injection, do not use
  this pen; contact customer service.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>8. Spillage
  from pen is observed.</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not use
  this pen; contact customer service.</span></p>
  </td>
 </tr>
 <tr>
  <td width=302 valign=top style='width:226.55pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>9. The dose
  knob inadvertently turned clockwise after completing the injection.</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>How do I
  reset the dose knob to the start position?</span></p>
  </td>
  <td width=302 valign=top style='width:226.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Do not press
  the push button. Reset the pen by simply turning back the dose knob
  anti-clockwise to the start position.</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>Distributor:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>Gedeon Richter
Plc.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>Gyömr&#337;i út
19-21.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>1103 Budapest,
Hungary</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>Legal
manufacturer:</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>Ypsomed AG</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>Brunnmattstrasse
6</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-AU>3401 Burgdorf,
Switzerland</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
